# Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma

> **NCT04976478** · — · NOT_YET_RECRUITING · sponsor: **Peking University Third Hospital** · enrollment: 125 (estimated)

## Conditions studied

- Cervical Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nimotuzumab
- **RADIATION:** EBRT combined with brachytherapy

## Key facts

- **NCT ID:** NCT04976478
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2021-07
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2021-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04976478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04976478, "Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04976478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*